RecruitingNCT06974305

PET/MRI/EEG Imaging Study in Epilepsy

Investigation of Interictal Metabolic and Electrophysiologic Changes in Epilepsy Through Trimodal Neuroimaging


Sponsor

Massachusetts General Hospital

Enrollment

30 participants

Start Date

Sep 21, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]). The study will also compare how the three imaging modalities localize regions of abnormal function in the brain.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Age 18 or older
  • Diagnosed with epilepsy with abnormal interictal EEG

Exclusion Criteria8

  • Contraindications to PET, MRI, or EEG imaging
  • History of severe brain disease such as stroke and head trauma
  • History of brain surgery
  • History of type I or II diabetes mellitus
  • Fasting plasma glucose level >200 mg/dL
  • Employed under direct supervision of the PI conducting the research
  • Current use of drugs that modulate brain function
  • Current or past history of major medical, neurological, or psychiatric conditions

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONFDG-PET/fMRI/EEG imaging

Subject will undergo simultaneous EEG, fMRI, and FDG-PET imaging. This includes the use of a standard injected radioactive marker used in PET imaging.


Locations(1)

Athinoula A. Martinos Center

Charlestown, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06974305


Related Trials